Microbot Medical Inc.
DB:CY9D Stock Report
Microbot Medical Balance Sheet Health
Financial Health criteria checks 6/6 Microbot Medical has a total shareholder equity of $6.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.4M and $1.4M respectively.
Key information Interest coverage ratio n/a Cash US$6.46m Equity US$6.06m Total liabilities US$1.38m Total assets US$7.43m
Recent financial health updates
Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 14
Microbot Medical Inc. announced delayed 10-Q filing May 17
Show all updates
Microbot Medical Inc., Annual General Meeting, Dec 17, 2024 Nov 07
Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial Oct 15
Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market Oct 14
Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Sep 17
Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center Jul 18
Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial Jul 08 Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million. Jul 02
Microbot Medical Inc. announced that it has received $1.762502 million in funding Jun 21
New major risk - Shareholder dilution Jun 06 Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million. Jun 06
Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.
New major risk - Share price stability Jun 03
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health Apr 30
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US Feb 06
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters Jan 30
New major risk - Shareholder dilution Jan 24
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study Jan 19
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met Dec 29
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study Dec 07
Microbot Medical Inc. Announces Executive Changes Nov 22
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process Nov 15
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study Nov 01 Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company Oct 20
Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System Oct 18
Microbot Medical Inc., Annual General Meeting, Nov 02, 2023 Sep 06
Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board Aug 11
Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office Jun 23
New major risk - Shareholder dilution Jun 08
Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System Jun 03
LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process Jun 01
Microbot Medical Inc. announced delayed 10-Q filing May 17
Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System May 10
Microbot Medical Inc. Announces Final Data from Its Recent Animal Study May 06
Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization May 04
Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel Dec 10
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance Nov 19
High number of new directors Nov 16
Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System Nov 04
Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board Nov 01
Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System Oct 19
Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System Oct 14
Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System Oct 12
Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop. Oct 08
Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment Oct 06
Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board Sep 20
Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board Sep 16
Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System Sep 13
Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board Sep 09
Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System Sep 07
Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month Sep 03
Microbot Medical Inc., Annual General Meeting, Sep 21, 2022 Aug 09
High number of new directors Apr 27
High number of new directors Apr 15
Microbot Medical Inc. Announces Executive Changes Apr 07
Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States Dec 24
Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology Jun 30
New 90-day high: €8.75 Feb 18
Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt Jan 29
New 90-day high: €7.00 Jan 26
Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System Jan 15
New 90-day low: €5.55 Dec 31
Microbot Medical Inc. Announces Successful Animal Study Utilizing Its Liberty™ Robotic System Sep 17
New 90-day low - €5.40 Sep 04
New 90-day high - €6.90 Aug 15
Financial Position Analysis
Short Term Liabilities: CY9D's short term assets ($7.1M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: CY9D's short term assets ($7.1M) exceed its long term liabilities ($38.0K).
Debt to Equity History and Analysis
Debt Level: CY9D is debt free.
Reducing Debt: CY9D had no debt 5 years ago.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CY9D has sufficient cash runway for 10 months based on last reported free cash flow , but has since raised additional capital.
Forecast Cash Runway: CY9D is forecast to have sufficient cash runway for 9 months based on free cash flow estimates , but has since raised additional capital.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}